R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, >80 years, or fail >75 years – an open label randomized Nordic Lymphoma group. Phase III trial- NLG-LBC7
Principal investigator: Sirpa Leppä
Trial site: HUS Comprehensive Cancer Center
Link to the ClinicalTrials.gov study website
